AstraZeneca Will Validate siRNA Delivery Technology For MDRNA In Shanghai Innovation Center
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Bothell, Washington-headquartered MDRNA announced recently that the company will collaborate with AstraZeneca to validate MDRNA's small interfering RNA (siRNA) technology for systemic delivery in hepatocellular carcinoma, one of the company's preclinical oncology programs